LAB vs NSC · rev $174.4M vs P/E 18, rev $12.12B
Standard Biotools Inc (LAB) versus Norfolk Southern Corporation (NSC) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Norfolk Southern Corporation (NSC) is a railroads company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported NSC revenue for 2024-12-31 was $12.12B. Net income was $2.62B. Revenue was down 0.3% from 2023-12-31 to 2024-12-31. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
LAB currently screens at market cap $317.1M. NSC currently screens at market cap $60.10B and trailing P/E 18.2.
Not investment advice. Open the LAB and NSC stock pages for the full models.
Not investment advice.